Geron (NASDAQ: GERN) — Company Overview, News & Financial Data
Geron develops oncology therapeutics, focusing on imetelstat for treating myeloid malignancies through clinical trials.
Geron
Geron (NASDAQ:GERN) focuses on the development and commercialization of therapeutics for oncology and other age-related diseases. Its most well-known project involves the development of its flagship drug, imetelstat, a novel telomerase inhibitor aimed at treating myeloid malignancies. The company's objective is to advance imetelstat through clinical trials, aiming for its commercialization as a treatment option for patients with hematologic malignancies. Geron's operations are chiefly concentrated on research and development activities, with a strong emphasis on innovation and collaboration with leaders in the field of oncology to potentially improve patient outcomes.
Snapshot
Operations
Products and/or services of Geron
- Imetelstat: An investigational drug targeting blood cancers by inhibiting the growth of cancer stem cells. It's not yet commercially available.
Geron executive team
- Harout SemerjianCEO, President & Director
- Michelle J. RobertsonEVP, CFO, Treasurer and Principal Financial & Accounting Officer
- Joseph Emile EidExecutive VP of Research & Development and Chief Medical Officer
- Ahmed ElNawawiExecutive VP & Chief Commercial Officer
- Shanthakumar TyavanagimattSenior VP & Chief Technical Officer
- Dawn SchottlandtSenior Vice President of Investor Relations & Corporate Affairs
- Timothy WilliamsExecutive VP, Chief Legal Officer & Corporate Secretary
- Aron FeingoldVice President of Investor Relations & Corporate Communications
- Shannon T. OdamExecutive VP & Chief People Officer
- Bryan RidgellSenior VP of Portfolio & Project Management and Chief of Staff